Fort Collins, Colorado, Feb. 12, 2024 (GLOBE NEWSWIRE) -- The Neurodegenerative Disease Market size was valued at USD 51.2 Billion in 2023 and is anticipated to reach USD 96.4 Billion by 2032 at a CAGR of 7.3%. A neurodegenerative disease occurs with the loss of neurons in the brain, resulting in fatality.

科罗拉多州柯林斯堡，2024年2月12日（环球通讯社）——2023年神经退行性疾病市场规模为512亿美元，预计到2032年将达到964亿美元，复合年增长率为7.3%。神经退行性疾病随着大脑神经元的丢失而发生，导致死亡。

Common occurrences include Parkinson’s disease, dementia, multiple sclerosis, and Alzheimer’s disease. Mostly, occurrences of Alzheimer’s and dementia happen in older adults with a prolonged history of brain-related disorders. On the other hand, nanotherapeutics emerge as a potential therapy for many cases to mitigate the risks associated with the disease.

常见的疾病包括帕金森病、痴呆症、多发性硬化症和阿尔茨海默病。大多数情况下，阿尔茨海默氏病和痴呆症的发生发生在有长期大脑相关疾病史的老年人身上。另一方面，纳米治疗剂作为许多病例的潜在疗法出现，以减轻与疾病相关的风险。

The field is evolving with a major focus on optimizing delivery strategies and expanding medical applications. The growing healthcare expenditure on research and development has been pivotal for the major success of drug development and research. Emerging therapies have received wider recognition, with many lucrative opportunities for future development.

该领域正在发展，主要关注优化交付策略和扩大医疗应用。不断增长的医疗保健研发支出对于药物开发和研究的重大成功至关重要。新兴疗法得到了更广泛的认可，为未来的发展提供了许多有利可图的机会。

The technological advances in drug discovery and biotechnology have immensely contributed to the emergence of novel treatment options. In addition, the COVID-19 pandemic has triggered the need for productive research on neurodegenerative disorders, which has sparked the interest of healthcare researchers.

药物发现和生物技术的技术进步极大地促进了新型治疗选择的出现。此外，新型冠状病毒肺炎引发了对神经退行性疾病进行有效研究的需求，这引发了医疗保健研究人员的兴趣。

As per WHO data for 2022, there will be a 20% rise in the geriatric population by 2026 across the globe. Also, the rate of Alzheimer’s and Parkinson’s disease is projected to grow in the geriatric population. Technological advancements such as biomarker identification, genetic testing, and neuroimaging contribute to the progression of targeted therapies.

根据世界卫生组织2022年的数据，到2026年，全球老年人口将增加20%。此外，老年痴呆症和帕金森病的发病率预计将在老年人群中增长。生物标志物鉴定，基因检测和神经影像学等技术进步有助于靶向治疗的进展。

Request Sample Report:  https://bit.ly/48fwCMv Segmentation Overview: The global neurodegenerative disease mar.

请求示例报告：https://bit.ly/48fwCMv分割概述：全球神经退行性疾病mar。